YONKERS, N.Y.--(BUSINESS WIRE)--Aug. 10, 2006--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that following an interim analysis of 30 patients treated with a 4.0ml dose of AVR118, as well as an additional 3 patients treated with a 1.0ml dose, the company is satisfied in concluding that AVR 118 can be given safely to patients with Type 2 diabetes. Contrary to previous reports, AVR118 had no apparent effects on blood glucose levels in patients receiving oral hypoglycemic therapies. Moreover, AVR118 had no demonstrable effect on blood chemistry, hematology, weight gain or lean body mass. These findings reinforce the belief that AVR 118 is extremely well tolerated and has no apparent effect on glucose metabolism.
